EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review

Shutaro Sumiyoshi, Takeshi Kubota, Hiroyuki Inoue, Kazuya Takabatake, Keiji Nishibeppu, Toshiyuki Kosuga, Hirotaka Konishi, Hitoshi Fujiwara, Atsushi Shiozaki

Cancer Diagnosis & Prognosis · 01.03.2026 · 6 (2) · 393-398

DOI: 10.21873/cdp.10538 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.03.2026. Verfasst von Shutaro Sumiyoshi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Immune checkpoint inhibitors (ICIs), including nivolumab, have markedly improved gastric cancer (GC) outcomes. However, immune-related adverse events involving the central nervous system are rare and potentially life-threatening. Limbic encephalitis is an exceptionally uncommon manifestation, and its clinical course remains poorly understood. We conducted a literature review of ICI-induced encephalitis specifically in patients with gastrointestinal cancers to clarify its clinical characteristics and management. Case Report: We describe the case of an 83-year-old man with unresectable advanced GC who received multiple lines of chemotherapy, including nivolumab as third-line therapy. After more than 40 cycles of nivolumab treatment, the patient developed progressive cognitive decline. Brain magnetic resonance imaging (MRI) revealed fluid attenuated inversion recovery hyperintensity in the right hippocampus, consistent with limbic encephalitis. Nivolumab was discontinued without corticosteroid administration, leading to gradual cognitive recovery. Follow-up MRI demonstrated resolution of hippocampal abnormalities. Conclusion: This case highlights an exceptionally rare instance of nivolumab-induced limbic encephalitis in a patient with GC. While our patient recovered spontaneously after drug discontinuation without corticosteroids, the key clinical implication is that new-onset cognitive decline in elderly patients receiving ICIs should not be misattributed to dementia progression. Early recognition of neurological immune-related adverse events is essential, as continued ICI therapy in unrecognized cases may result in irreversible or even fatal outcomes.

Schlagwörter

Stichwörter der Autor:innen

Gastric cancercase reportencephalitisnivolumab

Autor:innen und Institutionen

  • Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Surgery, Ayabe City Hospital, Kyoto, Japan.

Zitieren

APA

Sumiyoshi, S., Kubota, T., Inoue, H., Takabatake, K., Nishibeppu, K., Kosuga, T., Konishi, H., Fujiwara, H., & Shiozaki, A. (2026). Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review. Cancer Diagnosis & Prognosis, 6(2), 393-398. https://doi.org/10.21873/cdp.10538

Vancouver

Sumiyoshi S, Kubota T, Inoue H, Takabatake K, Nishibeppu K, Kosuga T, et al. Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review. Cancer Diagnosis & Prognosis. 2026;6(2):393-398. doi:10.21873/cdp.10538

BibTeX
@article{Sumiyoshi2026,
  author = {Sumiyoshi, Shutaro and Kubota, Takeshi and Inoue, Hiroyuki and Takabatake, Kazuya and Nishibeppu, Keiji and Kosuga, Toshiyuki and Konishi, Hirotaka and Fujiwara, Hitoshi and Shiozaki, Atsushi},
  title = {Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {393--398},
  doi = {10.21873/cdp.10538}
}
Kostenlos starten →